Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.69 |
| ▸ | CA9 | Q16790 | 14/20 | 0.69 |
| ▸ | CA1 | P00915 | 14/20 | 0.69 |
| ▸ | CA12 | O43570 | 11/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.69 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | RXRB | P28702 | 2/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926937 | 0.84 | CA2 (0.67) | CA2CA9CA1CA12CA14 | |
| SCHEMBL28032548 | 0.84 | CA2 (0.73) | CA2CA9CA1CA12CA14 | |
| SCHEMBL29374737 | 0.83 | CAMKK2 (0.59) | CA2CA9CA1CA12CA14 | |
| SCHEMBL2342732 | 0.83 | CAMKK2 (0.59) | CA2CA9CA1CA12CA14 | |
| SCHEMBL1874815 | 0.82 | CA2 (1.00) | CA2CA9CA1CA12CA14 | |
| SCHEMBL23226834 | 0.81 | CA12 (0.74) | CA2CA9CA1CA12CA14 | |
| SCHEMBL4132126 | 0.81 | NPC1 (0.54) | TRIM24TRIM33RXRARXRBRXRG | |
| SCHEMBL31670545 | 0.80 | CA1 (0.67) | CA2CA9CA1CA12CA14 | |
| SCHEMBL67270 | 0.80 | CA1 (0.67) | CA2CA9CA1CA12CA14 | |
| SCHEMBL30066684 | 0.80 | KMO (0.72) | TRIM24TRIM33RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021068950-A1 | AMIDE COMPOUND AND MEDICAL USE THEREOF AS STING INHIBITOR | 中国药科大学 | 2021-04-15 | — | — | WO | disclosed |
| US-7947684-B2 | anticoagulants; immunomoderators; antiinflammatory agents | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20040220171-A1 | 1-Aroyl-piperidinyl benzamidines | AVENTIS PHARMACEUTICALS INC | 2004-11-04 | — | — | US | disclosed |
| EP-1278732-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | Aventis Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020045613-A1 | 1-aroyl-piperidinyl benzamidines | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001081310-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220171-A1 | 1-Aroyl-piperidinyl benzamidines | TPSAB1, TPSB2, CMA1 | CA2 1410/4885CA9 1116/4885CA1 1496/4885 |
| US-20020045613-A1 | 1-aroyl-piperidinyl benzamidines | TPSAB1, TPSB2, CMA1 | CA2 1410/4885CA9 1116/4885CA1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.